PURPOSE: This study investigated the short-term response to a standardized hormonal therapy protocol for treatment of infantile spasms. METHODS: Twenty-seven children with video electroencephalography (EEG)-confirmed infantile spasms received very high dose (8 mg/kg/day, max 60 mg/day) oral prednisolone for 2 weeks. Response (absence of both hypsarrhythmia and spasms) to prednisolone was ascertained by repeat overnight video-EEG. Responders were tapered over 2 weeks and nonresponders were immediately transitioned to high dose (150 IU/m(2)/day) intramuscular adrenocorticotropic hormone (ACTH) for two additional weeks. Response was again determined by overnight video-EEG after ACTH therapy. KEY FINDINGS: Sixty-three percent (17/27) of patients responded completely to prednisolone. Subsequently, 40% (4/10) of prednisolone nonresponders exhibited a complete response after an additional 2-week course with ACTH. Among 27 subjects with median follow-up of 13.5 months (interquartile range [IQR] 4.8-25.9), 12% (2/17) of prednisolone responders and 50% (2/4) of ACTH responders experienced a relapse between 2 and 9 months after initial response. SIGNIFICANCE: Very high dose prednisolone demonstrated significantly higher efficacy than previously reported for lower doses in prior studies. High dose ACTH may be superior to very high dose prednisolone, and in lieu of a definitive clinical trial, the choice between prednisolone and ACTH for initial treatment of infantile spasms remains controversial. Wiley Periodicals, Inc.
PURPOSE: This study investigated the short-term response to a standardized hormonal therapy protocol for treatment of infantile spasms. METHODS: Twenty-seven children with video electroencephalography (EEG)-confirmed infantile spasms received very high dose (8 mg/kg/day, max 60 mg/day) oral prednisolone for 2 weeks. Response (absence of both hypsarrhythmia and spasms) to prednisolone was ascertained by repeat overnight video-EEG. Responders were tapered over 2 weeks and nonresponders were immediately transitioned to high dose (150 IU/m(2)/day) intramuscular adrenocorticotropic hormone (ACTH) for two additional weeks. Response was again determined by overnight video-EEG after ACTH therapy. KEY FINDINGS: Sixty-three percent (17/27) of patients responded completely to prednisolone. Subsequently, 40% (4/10) of prednisolone nonresponders exhibited a complete response after an additional 2-week course with ACTH. Among 27 subjects with median follow-up of 13.5 months (interquartile range [IQR] 4.8-25.9), 12% (2/17) of prednisolone responders and 50% (2/4) of ACTH responders experienced a relapse between 2 and 9 months after initial response. SIGNIFICANCE: Very high dose prednisolone demonstrated significantly higher efficacy than previously reported for lower doses in prior studies. High dose ACTH may be superior to very high dose prednisolone, and in lieu of a definitive clinical trial, the choice between prednisolone and ACTH for initial treatment of infantile spasms remains controversial. Wiley Periodicals, Inc.
Authors: Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne Journal: Lancet Date: 2004 Nov 13-19 Impact factor: 79.321
Authors: Finbar J K O'Callaghan; Andrew L Lux; Katrina Darke; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Christopher M Verity; John P Osborne Journal: Epilepsia Date: 2011-06-10 Impact factor: 5.864
Authors: John M Pellock; Richard Hrachovy; Shlomo Shinnar; Tallie Z Baram; David Bettis; Dennis J Dlugos; William D Gaillard; Patricia A Gibson; Gregory L Holmes; Douglas R Nordl; Christine O'Dell; W Donald Shields; Edwin Trevathan; James W Wheless Journal: Epilepsia Date: 2010-10 Impact factor: 5.864
Authors: Carlos J Ballester-Rosado; John T Le; Trang T Lam; Carrie A Mohila; Sandi Lam; Anne E Anderson; James D Frost; John W Swann Journal: Ann Neurol Date: 2022-05-10 Impact factor: 11.274
Authors: Kelly G Knupp; Jason Coryell; Katherine C Nickels; Nicole Ryan; Erin Leister; Tobias Loddenkemper; Zachary Grinspan; Adam L Hartman; Eric H Kossoff; William D Gaillard; John R Mytinger; Sucheta Joshi; Renée A Shellhaas; Joseph Sullivan; Dennis Dlugos; Lorie Hamikawa; Anne T Berg; John Millichap; Douglas R Nordli; Elaine Wirrell Journal: Ann Neurol Date: 2016-02-13 Impact factor: 10.422
Authors: John R Mytinger; Dara V F Albert; Jaime D Twanow; Jorge Vidaurre; Yubo Tan; Guy N Brock; Adam P Ostendorf Journal: Pediatr Neurol Date: 2019-12-03 Impact factor: 4.210
Authors: Shaun A Hussain; Ernst Schmid; Jurriaan M Peters; Monisha Goyal; E Martina Bebin; Hope Northrup; Mustafa Sahin; Darcy A Krueger; Joyce Y Wu Journal: Epilepsy Res Date: 2018-10-02 Impact factor: 2.991